课题基金 / 基金详情

Drug Safety and Effectiveness Network (DSEN) Pharmacogenomics of Adverse Events National Team(PREVENT)

Drug Safety and Effectiveness Network (DSEN) Pharmacogenomics of Adverse Events National Team(PREVENT)
药物安全性和有效性网络 (DSEN) 不良事件药物基因组学国家小组（预防）
批准号：
237872
负责人：
Hayden Michael R
金额：
$117.07万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Directed Grant
财政年份：
2011
资助国家：
加拿大
项目状态：
已结题
起止时间：
2011-06-01 至 2014-06-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=237872&lang=en
关键词：
Adverse Drug Reaction Drug Response Drug Safety Genetics Genomics Pharmacogenetics Pharmacogenomics Pharmacokinetics Pharmacology

项目摘要

项目成果

Hayden Michael R的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Adverse drug reactions (ADRs) are the 4th leading cause of death and cause an estimated 200,000 severe ADRs each year in Canada. Despite the promise of improved medicines, withdrawals of new drugs (eg. Rezulin, Vioxx) demonstrate the need to identify pati
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Allele-specific lowering of mutant polyQ proteins as treatment for Huntington disease, spinocerebellar ataxia type 3 and spinocerebellar ataxia type 7
Novel Approaches Directed to Prevention and Treatment of Huntington Disease
Canada Research Chair Tier 1
  • 批准号：
    315426
  • 项目类别：
  • 资助金额：
    $101.99万
  • 财政年份：
    2014
  • 负责人：
    Hayden Michael R
  • 依托单位：
    University of British Columbia
Novel approaches to modulate key targets in the pathogenesis of Huntington Disease
海外基金